We showed for the first time that targeted therapy of NB tumors with the CXCR4-A-Fc antagonist delivered by OVV not only reduced tumor load in the syngeneic tumor-bearing mice, but also reprogrammed the TME to effectively augment the efficacy of whole tumor cell lysate-loaded DC vaccines by producing a more permissive environment for induction of antitumor immunity. Here, CXCR4 is linked to neoplasm.